Hepatocellular carcinoma

00:00 / 00:00

High Yield Notes

18 pages

Flashcards

Hepatocellular carcinoma

of complete

Questions

USMLE® Step 1 style questions USMLE

of complete

A 67-year-old man comes to the clinic due to worsening fatigue and abdominal distension. The patient has lost 11 pounds in the last 2 months with minimal change in appetite. Past medical history is notable for chronic liver disease due to hepatitis B infection that was diagnosed 15 years ago. His most recent colonoscopy 1 year ago showed no abnormalities. His temperature is 37.0°C (98.6°F), pulse is 85/min, and blood pressure is 154/89 mm Hg. Physical examination reveals temporal wasting and scleral icterus. Palmar erythema and multiple spider angiomas are present. The abdomen is distended with shifting dullness to percussion. There is 2+ pitting edema of the lower extremities. Ultrasound shows a single homogenous liver mass with irregular borders. Which of the following best describes the tumor marker that is likely elevated in this patient?

External References

First Aid

2024

2023

2022

2021

Aflatoxin

hepatocellular carcinoma p. 399

α-fetoprotein

in hepatocellular carcinoma p. 399

Anorexia

liver cancer/tumors p. 399

Ascites

hepatocellular carcinoma p. 399

Fatty liver disease

hepatocellular carcinoma and p. 399

Hemochromatosis p. 402

hepatocellular carcinoma and p. 399

Hepatitis C (HCV)

hepatocellular carcinoma and p. 399

Hepatomegaly

hepatocellular carcinoma p. 399

Jaundice p. 400

hepatocellular carcinoma p. 399

Metastases p. 399

liver cancer p. 399

Polycythemia/vera p. 438

hepatocellular carcinoma p. 399

Transcript

Watch video only

Content Reviewers

As opposed to benign hepatic tumors, malignant hepatic tumors are cancerous, very severe, and are actually now the third leading cause of cancer deaths worldwide.

With these malignant liver cells or hepatocytes, just like malignant cells in other cancers, they develop some mutation that causes them to replicate at way higher rates and form these masses of cells that continue to grow and potentially spread to other tissues.

This would be a primary hepatic tumor, since it starts in the liver. It’s totally possible, though, for liver tumor to develop as a metastasis from another primary cancer, in which case it would not be hepatocellular carcinoma, but a carcinoma from somewhere else, and this is actually more common than primary liver tumors themselves.

The most common sources of the tumor cells that got to the liver but started somewhere else are the colon, pancreas, lung and breast.

What exactly causes the mutation in the hepatocyte though?

Well the mechanism isn’t fully understood and can probably be caused by a lot of different things, most importantly though, things that put the liver in a constant cycle of damage and repair are the biggest culprits.

If the liver cells are constantly being forced to repair, this raises the chances of genetic mistakes or mutations, potentially leading to carcinogenesis or development of cancer cells.

Examples might be any disease that leads to cirrhosis and scarring of the liver tissue, which can include alcoholic hepatitis and cirrhosis, hereditary hemochromatosis, primary biliary cirrhosis, alpha-1 antitrypsin deficiency, and others.

The most common risk factor, the ones that have been linked the most with hepatocellular carcinoma are the hepatitis B and hepatitis C viruses, both of which can become chronic or long-lasting.

In this case, these cells are at greater risk because of the constant state of infection and immune cell attack, leading to constant damage and repair.

HBV is particularly problematic because of how the virus replicates; the HBV virus is a DNA virus that integrates into the hepatocyte’s DNA, which, although not completely understood, is thought to either directly disrupt regulation of cell growth and replication, leading to carcinoma, or alternatively cause some indirect effect that later leads to unchecked cell growth and replication.

Elsevier

Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX